001     280050
005     20250824001729.0
024 7 _ |a 10.1080/21678421.2025.2468404
|2 doi
024 7 _ |a pmid:39985291
|2 pmid
024 7 _ |a 2167-8421
|2 ISSN
024 7 _ |a 2167-9223
|2 ISSN
024 7 _ |a altmetric:174731705
|2 altmetric
037 _ _ |a DZNE-2025-00887
041 _ _ |a English
082 _ _ |a 610
100 1 _ |a Steinfurth, Laura
|0 0000-0001-5503-1742
|b 0
245 _ _ |a Self-assessment of amyotrophic lateral sclerosis functional rating scale on the patient's smartphone proves to be non-inferior to clinic data capture.
260 _ _ |a Abingdon
|c 2025
|b Taylor Francis Group
336 7 _ |a article
|2 DRIVER
336 7 _ |a Output Types/Journal article
|2 DataCite
336 7 _ |a Journal Article
|b journal
|m journal
|0 PUB:(DE-HGF)16
|s 1753362620_6042
|2 PUB:(DE-HGF)
336 7 _ |a ARTICLE
|2 BibTeX
336 7 _ |a JOURNAL_ARTICLE
|2 ORCID
336 7 _ |a Journal Article
|0 0
|2 EndNote
520 _ _ |a To investigate self-assessment of the amyotrophic lateral sclerosis functional rating scale-revised (ALSFRS-R) using the patient's smartphone and to analyze non-inferiority to clinic assessment.In an observational study, ALSFRS-R data being remotely collected on a mobile application (App-ALSFRS-R) were compared to ALSFRS-R captured during clinic visits (clinic-ALSFRS-R). ALS progression rate (ALSPR)-as calculated by the monthly decline of ALSFRS-R-and its intrasubject variability (ALSPR-ISV) between ratings were used to compare both cohorts. To investigate non-inferiority of App-ALSFRS-R data, a non-inferiority margin was determined.A total of 691 ALS patients using the ALS-App and 1895 patients with clinic assessments were included. Clinical characteristics for the App-ALSFRS-R and clinic-ALSFRS-R cohorts were as follows: Mean age 60.45 (SD 10.43) and 63.69 (SD 11.30) years (p < 0.001), disease duration 38.7 (SD 37.68) and 56.75 (SD 54.34) months (p < 0.001) and ALSPR 0.72 and 0.59 (p < 0.001), respectively. A paired sample analysis of ALSPR-ISV was applicable for 398 patients with clinic as well as app assessments and did not show a significant difference (IQR 0.12 [CI 0.11, 0.14] vs 0.12 [CI 0.11, 0.14], p = 0.24; Cohen's d = 0.06). CI of IQR for App-ALSFRS-R was below the predefined non-inferiority margin of 0.15 IQR, demonstrating non-inferiority.Patients using a mobile application for remote digital self-assessment of the ALSFRS-R revealed younger age, earlier disease course, and faster ALS progression. The finding of non-inferiority of App-ALSFRS-R assessments underscores, that data collection using the ALS-App on the patient's smartphone can serve as additional source of ALSFRS-R in ALS research and clinical practice.
536 _ _ |a 353 - Clinical and Health Care Research (POF4-353)
|0 G:(DE-HGF)POF4-353
|c POF4-353
|f POF IV
|x 0
588 _ _ |a Dataset connected to CrossRef, PubMed, , Journals: pub.dzne.de
650 _ 7 |a ALS-App
|2 Other
650 _ 7 |a Amyotrophic lateral sclerosis
|2 Other
650 _ 7 |a amyotrophic lateral sclerosis functional rating scale-revised
|2 Other
650 _ 7 |a remote assessment
|2 Other
650 _ 7 |a self-assessment
|2 Other
650 _ 2 |a Humans
|2 MeSH
650 _ 2 |a Amyotrophic Lateral Sclerosis: diagnosis
|2 MeSH
650 _ 2 |a Amyotrophic Lateral Sclerosis: psychology
|2 MeSH
650 _ 2 |a Amyotrophic Lateral Sclerosis: physiopathology
|2 MeSH
650 _ 2 |a Male
|2 MeSH
650 _ 2 |a Smartphone
|2 MeSH
650 _ 2 |a Female
|2 MeSH
650 _ 2 |a Middle Aged
|2 MeSH
650 _ 2 |a Aged
|2 MeSH
650 _ 2 |a Mobile Applications
|2 MeSH
650 _ 2 |a Self-Assessment
|2 MeSH
650 _ 2 |a Disease Progression
|2 MeSH
650 _ 2 |a Severity of Illness Index
|2 MeSH
650 _ 2 |a Cohort Studies
|2 MeSH
700 1 _ |a Grehl, Torsten
|b 1
700 1 _ |a Weyen, Ute
|b 2
700 1 _ |a Kettemann, Dagmar
|b 3
700 1 _ |a Steinbach, Robert
|b 4
700 1 _ |a Rödiger, Annekathrin
|b 5
700 1 _ |a Grosskreutz, Julian
|b 6
700 1 _ |a Petri, Susanne
|b 7
700 1 _ |a Boentert, Matthias
|b 8
700 1 _ |a Weydt, Patrick
|0 P:(DE-2719)9001116
|b 9
|u dzne
700 1 _ |a Bernsen, Sarah
|0 P:(DE-2719)9000485
|b 10
|u dzne
700 1 _ |a Walter, Bertram
|b 11
700 1 _ |a GüNTHER, René
|0 P:(DE-2719)2811849
|b 12
|u dzne
700 1 _ |a Lingor, Paul
|0 P:(DE-2719)2812561
|b 13
700 1 _ |a Koch, Jan Christoph
|b 14
700 1 _ |a Baum, Petra
|b 15
700 1 _ |a Weishaupt, Jochen H
|b 16
700 1 _ |a Dorst, Johannes
|0 P:(DE-2719)9001951
|b 17
|u dzne
700 1 _ |a Koc, Yasemin
|b 18
700 1 _ |a Cordts, Isabell
|b 19
700 1 _ |a Vidovic, Maximilian
|b 20
700 1 _ |a Norden, Jenny
|b 21
700 1 _ |a Schumann, Peggy
|b 22
700 1 _ |a Körtvelyessy, Peter
|0 P:(DE-2719)2812030
|b 23
|u dzne
700 1 _ |a Spittel, Susanne
|b 24
700 1 _ |a Münch, Christoph
|b 25
700 1 _ |a Maier, André
|b 26
700 1 _ |a Meyer, Thomas
|0 0000-0002-2736-7350
|b 27
773 _ _ |a 10.1080/21678421.2025.2468404
|g Vol. 26, no. 5-6, p. 495 - 506
|0 PERI:(DE-600)2705061-0
|n 5-6
|p 495 - 506
|t Amyotrophic lateral sclerosis & frontotemporal degeneration
|v 26
|y 2025
|x 2167-8421
856 4 _ |u https://pub.dzne.de/record/280050/files/DZNE-2025-00887.pdf
|y OpenAccess
856 4 _ |u https://pub.dzne.de/record/280050/files/DZNE-2025-00887.pdf?subformat=pdfa
|x pdfa
|y OpenAccess
909 C O |o oai:pub.dzne.de:280050
|p openaire
|p open_access
|p VDB
|p driver
|p dnbdelivery
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 9
|6 P:(DE-2719)9001116
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 10
|6 P:(DE-2719)9000485
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 12
|6 P:(DE-2719)2811849
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 13
|6 P:(DE-2719)2812561
910 1 _ |a Deutsches Zentrum für Neurodegenerative Erkrankungen
|0 I:(DE-588)1065079516
|k DZNE
|b 17
|6 P:(DE-2719)9001951
910 1 _ |a External Institute
|0 I:(DE-HGF)0
|k Extern
|b 23
|6 P:(DE-2719)2812030
913 1 _ |a DE-HGF
|b Gesundheit
|l Neurodegenerative Diseases
|1 G:(DE-HGF)POF4-350
|0 G:(DE-HGF)POF4-353
|3 G:(DE-HGF)POF4
|2 G:(DE-HGF)POF4-300
|4 G:(DE-HGF)POF
|v Clinical and Health Care Research
|x 0
914 1 _ |y 2025
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0200
|2 StatID
|b SCOPUS
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0160
|2 StatID
|b Essential Science Indicators
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0600
|2 StatID
|b Ebsco Academic Search
|d 2025-01-01
915 _ _ |a Creative Commons Attribution-NonCommercial-NoDerivs CC BY-NC-ND 4.0
|0 LIC:(DE-HGF)CCBYNCND4
|2 HGFVOC
915 _ _ |a JCR
|0 StatID:(DE-HGF)0100
|2 StatID
|b AMYOTROPH LAT SCL FR : 2022
|d 2025-01-01
915 _ _ |a WoS
|0 StatID:(DE-HGF)0113
|2 StatID
|b Science Citation Index Expanded
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0150
|2 StatID
|b Web of Science Core Collection
|d 2025-01-01
915 _ _ |a IF < 5
|0 StatID:(DE-HGF)9900
|2 StatID
|d 2025-01-01
915 _ _ |a OpenAccess
|0 StatID:(DE-HGF)0510
|2 StatID
915 _ _ |a Peer Review
|0 StatID:(DE-HGF)0030
|2 StatID
|b ASC
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0300
|2 StatID
|b Medline
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)1110
|2 StatID
|b Current Contents - Clinical Medicine
|d 2025-01-01
915 _ _ |a DBCoverage
|0 StatID:(DE-HGF)0199
|2 StatID
|b Clarivate Analytics Master Journal List
|d 2025-01-01
920 1 _ |0 I:(DE-2719)1011001
|k Clinical Research (Bonn)
|l Clinical Research Coordination
|x 0
920 1 _ |0 I:(DE-2719)5000075
|k AG Radbruch
|l Clinical Neuroimaging
|x 1
920 1 _ |0 I:(DE-2719)1710012
|k AG Falkenburger
|l Translational Parkinson Research
|x 2
920 1 _ |0 I:(DE-2719)1111015
|k Clinical Research (Munich)
|l Clinical Research (Munich)
|x 3
920 1 _ |0 I:(DE-2719)5000077
|k Clinical Study Center (Ulm)
|l Clinical Study Center (Ulm)
|x 4
980 _ _ |a journal
980 _ _ |a VDB
980 _ _ |a UNRESTRICTED
980 _ _ |a I:(DE-2719)1011001
980 _ _ |a I:(DE-2719)5000075
980 _ _ |a I:(DE-2719)1710012
980 _ _ |a I:(DE-2719)1111015
980 _ _ |a I:(DE-2719)5000077
980 1 _ |a FullTexts


LibraryCollectionCLSMajorCLSMinorLanguageAuthor
Marc 21